This randomized phase III trial studies how well eflornithine works compared to sulindac in preventing the return of the disease (recurrence) of high-risk adenomas and second primary disease in patients with stage 0-III colon or rectal cancer. Drugs used in chemotherapy, such as eflornithine and sulindac, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether eflornithine is more effective than sulindac when given alone or in combination in preventing recurrence of cancer.
This trial studies if myopenia (low muscle mass) plays a role in experiencing side effects from chemotherapy in older patients with colorectal cancer that has spread to other areas of the body (metastatic). Chemotherapy treatments for colorectal cancer can cause side effects such as low blood counts, nausea and vomiting, or mouth sores. Researchers are trying to determine if muscle mass has a role in how bad side effects from chemotherapy can be.